Market closedNon-fractional

EyePoint Pharmaceuticals/EYPT

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.

Ticker

EYPT

Sector

Healthcare

Trading on

NASDAQ

Industry

Pharmaceuticals

Headquarters

Watertown, United States

Employees

121

EYPT Metrics

BasicAdvanced
$449M
Market cap
-
P/E ratio
-$1.85
EPS
1.72
Beta
-
Dividend rate
$449M
1.72
5.077
4.832
1.85
2.323
-196.86%
-22.12%
-48.07%
7.369
1.72
1.72
-22.133
25.70%
-32.67%
13.43%
-12.54%

What the Analysts think about EYPT

Analyst Ratings

Majority rating from 11 analysts.
Buy

EYPT Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-251.72% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$12M
-17.14%
Net income
-$29M
108.57%
Profit margin
-251.72%
151.72%

EYPT Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 32.21%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.61
-$0.33
-$0.33
-$0.55
-
Expected
$0.60
-$0.51
-$0.49
-$0.42
-$0.52
Surprise
-201.88%
-35.65%
-32.11%
32.21%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for EyePoint Pharmaceuticals stock?

EyePoint Pharmaceuticals (EYPT) has a market cap of $449M as of July 06, 2024.

What is the P/E ratio for EyePoint Pharmaceuticals stock?

The price to earnings (P/E) ratio for EyePoint Pharmaceuticals (EYPT) stock is 0 as of July 06, 2024.

Does EyePoint Pharmaceuticals stock pay dividends?

No, EyePoint Pharmaceuticals (EYPT) stock does not pay dividends to its shareholders as of July 06, 2024.

When is the next EyePoint Pharmaceuticals dividend payment date?

EyePoint Pharmaceuticals (EYPT) stock does not pay dividends to its shareholders.

What is the beta indicator for EyePoint Pharmaceuticals?

EyePoint Pharmaceuticals (EYPT) has a beta rating of 1.72. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell EyePoint Pharmaceuticals stock

Buy or sell EyePoint Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing